Abstract:Abstract Frequent inactivation of transforming growth factor β (TGFβ) pathway core components in pancreatic ductal adenocarcinoma (PDA), especially the transcription factor SMAD4, suggests that TGFβ signaling is tumor suppressive in the pancreas. Yet, 50% of PDA retains an intact core TGFβ pathway, suggesting that there are mechanisms by which these tumors escape TGFβ-mediated tumor suppression. In unpublished work, we have delineated a mechanism for TGFβ-mediated tumor suppression via a lethal epithelial-mesenchymal transition (EMT). Based on clinical and in vitro evidence that AKT activation may suppress the lethal EMT response to TGFβ, we are investigating the role of AKT signaling in directly interfering with TGFβ-mediated tumor suppression. We have taken two major approaches: (1) to test the concept that AKT inhibition may reactivate TGFβ-mediated tumor suppression, we are chemically inhibiting AKT in PDA mouse models competent and deficient in TGFβ signaling, and (2) to understand the mechanism of AKT-TGFβ crosstalk in PDA progression, we are performing RNAseq-based gene expression profiling of SMAD4-restored PDA cell lines. We have found that in vitro, AKT signaling determines whether TGFβ induces apoptosis in SMAD4-restored PDA cell lines, and by gene expression analysis, we have identified a group of genes that are differentially regulated by TGFβ in the presence and absence of AKT signaling. Furthermore, we have characterized FOXO immunohistochemical staining as a reliable marker for AKT inhibition status and developed an in vivo system in which we are testing whether AKT inhibition may be a means to reactivate TGFβ-mediated tumor suppression in PDA. Our studies indicate that AKT signaling may alter the outcome of TGFβ-mediated tumor suppression in the pancreas, and our ongoing work is aimed at dissecting the AKT-modulated transcriptional mechanisms that determine the outcome of TGFβ signaling and the consequences of this crosstalk in tumor progression. Citation Format: Yun-Han Huang, Charles David, Joan Massague. AKT activation as a mechanism of escape from TGFβ-mediated lethal EMT. [abstract]. In: Proceedings of the AACR Special Conference: Developmental Biology and Cancer; Nov 30-Dec 3, 2015; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Res 2016;14(4_Suppl):Abstract nr A30.

Abrogation of Transforming Growth Factor- Β Signaling in Pancreatic Cancer

[Crosstalk Between Canonical TGF-β/Smad and Wnt/β-catenin Signaling Pathway].

TGF-β inhibits growth of pancreatic ductal epithelial cells through receptor-mediated activation of Smad proteins

TGF-β in Pancreatic Cancer Initiation and Progression: Two Sides of the Same Coin

The role of TGF-β/SMAD4 signaling in cancer

TGF-β-Regulated MicroRNAs and Their Function in Cancer Biology.

Transforming Growth Factor-β Signaling in Fibrotic Diseases and Cancer-Associated Fibroblasts

A Perspective on the Development of TGF-β Inhibitors for Cancer Treatment

TGF-β Tumor Suppression Through a Lethal EMT

Biphasic Role of TGF-β in Cancer Progression: From Tumor Suppressor to Tumor Promotor

Abstract A30: AKT Activation As a Mechanism of Escape from TGFβ-mediated Lethal EMT

Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1

The TGF-β superfamily as potential therapeutic targets in pancreatic cancer

Targeting the transforming growth factor-β signaling pathway in human cancer

TGF-beta Signaling in Cancer

Inhibition of Transforming Growth Factor β Signaling Reduces Pancreatic Adenocarcinoma Growth and Invasiveness

Tumor-stroma TGF-β1-THBS2 feedback circuit drives pancreatic ductal adenocarcinoma progression via integrin αvβ3/CD36-mediated activation of the MAPK pathway

TGF-β Signaling in Cell Fate Control and Cancer.

TGFbeta1 represses proliferation of pancreatic carcinoma cells which correlates with Smad4-independent inhibition of ERK activation

Targeting TGF-β Signaling in Cancer.

Targeting TGFβ signal transduction for cancer therapy